🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study

Recruitingn/aAges 18 Years - anyAlliOMEDICO AG
NCT06607302 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Cholangiocarcinoma is a rare and aggressive tumor of the bile duct associated with a poor prognosis and very limited treatment options. The IDH1 inhibitor ivosidenib provides a new, targeted treatment option for this disease. Ivosidenib was approved by European Medicines Agency (EMA) in May 2023 as monotherapy in adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. The prospective, multicenter, observational study IDHIRA will collect first real-world data on ivosidenib treatment in a broad patient population in Germany. Ivosidenib will be administered according to the current SmPC. Thus, IDHIRA will generate real-world evidence on effectiveness, quality of life (QoL) and safety of ivosidenib.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18 years or older. * Histologically confirmed locally advanced or metastatic CCC with a documented IDH1 R132 mutation diagnosed by an appropriate diagnostic test * Patients must have at least one prior systemic therapy * Decision for treatment with ivosidenib according to current SmPC. * Signed written informed consent before or within 6 weeks of first ivosidenib dose (inclusion of patients up to 6 weeks after first ivosidenib intake is allowed for patients not participating in the PRO module) * For patients participating in the PRO module (optional): * Dated signature of informed consent form before start of study treatment. * Willingness and capability to participate in PRO assessment in German language. * Other criteria according to current SmPC. Exclusion Criteria: * Participation in an interventional clinical trial within 30 days prior to enrolment or concurrent participation in an interventional clinical trial except for the follow-up period. * Other contraindications according to current SmPC.
💊

What it tests

  • Not listed
📍

Where

19 sites
Universitätsklinikum Augsburg, II. Medizinische Klinik
Augsburg, Germany
Hämatologisch-Onkologische Schwerpunktpraxis in Bad Liebenwerda
Bad Liebenwerda, Germany
Caritas Krankenhaus Bad Mergentheim
Bad Mergentheim, Germany
Onkologische Schwerpunktpraxis Bamberg
Bamberg, Germany
DRK Kliniken Berlin, Klinik für Innere Medizin
Berlin, Germany
Onkologisches Versorgungszentrum Berlin MVZ
Berlin, Germany
Sana Klinikum Lichtenberg, Innere Medizin IV
Berlin, Germany
Gemeinschaftspraxis Hämatologie - Onkologie
Dresden, Germany

…and 11 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy